HetrombopagAlternative Names: Hetrombopag olamine; SHR 8735 olamine
Latest Information Update: 25 Jul 2017
Price : *
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antihaemorrhagics; Small molecules
- Mechanism of Action Thrombopoietin stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Idiopathic thrombocytopenic purpura
Most Recent Events
- 30 Jul 2018 Jiangsu HengRui Medicine plans a phase I trial in healthy male volunteers (PO, tablet) in China (NCT03603132)
- 15 Jun 2018 Jiangsu HengRui Medicine plans a phase I/II trial for severe Aplastic anemia in China (NCT03557099)
- 30 Jun 2017 Phase-III clinical trials in Idiopathic thrombocytopenic purpura in China (PO) (NCT03222843)